Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 15/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.67 |
| ▸ | MLNR | O43193 | 1/20 | 0.67 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.67 |
| ▸ | HTR3B | O95264 | 1/20 | 0.67 |
| ▸ | HMGCR | P04035 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.67 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13566537 | 1.00 | HTR4 (0.72) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL9021868 | 0.99 | HTR4 (0.71) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL9021859 | 0.99 | HTR4 (0.71) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL9021862 | 0.99 | HTR4 (0.71) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1906067 | 0.97 | HTR4 (0.74) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9021715 | 0.97 | HTR4 (0.74) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9021703 | 0.97 | HTR4 (0.74) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9022409 | 0.97 | HTR4 (0.74) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9022397 | 0.97 | HTR4 (0.74) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL9022487 | 0.96 | HTR4 (0.73) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524736-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARMETHEON, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524736-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARMETHEON, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130040987-A1 | Stereoisomeric Compounds and Methods for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARMETHEON, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040987-A1 | Stereoisomeric Compounds and Methods for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARMETHEON, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8138204-B2 | Emesis, dyspepsia, gastroparesis, constipation, gastroesophageal reflux, or post-operative ileus; cisapride analogs; side effect reduction of adverse events; (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate or salts | ARYX THERAPEUTICS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138204-B2 | Emesis, dyspepsia, gastroparesis, constipation, gastroesophageal reflux, or post-operative ileus; cisapride analogs; side effect reduction of adverse events; (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate or salts | ARYX THERAPEUTICS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-7629466-B2 | Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085921-A1 | Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders | ARYX THERAPEUTICS (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085921-A1 | Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders | ARYX THERAPEUTICS (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080076927-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7326787-B2 | Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7282509-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282509-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070078265-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS (US) | 2007-04-05 | — | — | US | disclosed |
| US-7176218-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176218-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085921-A1 | Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR4 70/4885KCNH2 2450/4885CYP3A4 411/4885 |
| US-20080076927-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR4 193/4885KCNH2 3202/4885CYP3A4 150/4885 |
| US-20130040987-A1 | Stereoisomeric Compounds and Methods for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR4 70/4885KCNH2 2450/4885CYP3A4 411/4885 |
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | CCKBR, HRH2, GRPR | HTR4 71/4885KCNH2 1746/4885CYP3A4 400/4885 |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR4 193/4885KCNH2 3202/4885CYP3A4 150/4885 |
| US-20070078265-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR4 193/4885KCNH2 3202/4885CYP3A4 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.